<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<colgroup>
<col width="17.3%"></col>
<col width="82.7%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP2D6</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent μ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome.<br/> <br/>After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease and the M1 plasma concentration will increase which could increase or prolong therapeutic effects but also increase adverse reactions related to opioid toxicity, and may cause potentially fatal respiratory depression <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">If concomitant use of a CYP2D6 inhibitor is necessary, follow patients closely for adverse reactions including opioid withdrawal, seizures, and serotonin syndrome.<br/> <br/>If a CYP2D6 inhibitor is discontinued, consider lowering tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved. Follow patients closely for adverse events including respiratory depression and sedation.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Quinidine, fluoxetine, paroxetine and bupropion<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP3A4</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of tramadol hydrochloride extended-release tablets and CYP3A4 inhibitors can increase the plasma concentration of tramadol and may result in a greater amount of metabolism via CYP2D6 and greater levels of M1. Follow patients closely for increased risk of serious adverse events including seizures and serotonin syndrome, and adverse reactions related to opioid toxicity including potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved.<br/> <br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the tramadol plasma concentration will decrease <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>],</content> resulting in decreased opioid efficacy and possibly signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">If concomitant use is necessary, consider dosage reduction of tramadol hydrochloride extended-release tablets until stable drug effects are achieved. Follow patients closely for seizures and serotonin syndrome, and signs of respiratory depression and sedation at frequent intervals. If a CYP3A4 inhibitor is discontinued, consider increasing the tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved and follow patients for signs and symptoms of opioid withdrawal.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir)<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A4 Inducers</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of tramadol hydrochloride extended-release tablets and CYP3A4 inducers can decrease the plasma concentration of tramadol <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to tramadol, <content stylecode="italics">[see <linkhtml href="#Section_5.4">Warnings and Precautions (5.5)</linkhtml>]</content>.<br/> <br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the tramadol plasma concentration will increase <content stylecode="italics">[see <linkhtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause seizures and serotonin syndrome, and potentially fatal respiratory depression.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">If concomitant use is necessary, consider increasing the tramadol hydrochloride extended-release tablets dosage until stable drug effects are achieved. Follow patients for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider tramadol hydrochloride extended-release tablets dosage reduction and monitor for seizures and serotonin syndrome, and signs of sedation and respiratory depression. <br/> <br/>Patients taking carbamazepine, a CYP3A4 inducer, may have a significantly reduced analgesic effect of tramadol. Because carbamazepine increases tramadol metabolism and because of the seizure risk associated with tramadol, concomitant administration of tramadol hydrochloride extended-release tablets and carbamazepine is not recommended.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Rifampin, carbamazepine, phenytoin<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see <linkhtml href="#Section_5.5">Warnings and Precautions (5.6)</linkhtml>]</content>.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Serotonergic Drugs</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue tramadol hydrochloride extended-release tablets if serotonin syndrome is suspected.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">MAOI interactions with opioids may manifest as serotonin syndrome <content stylecode="italics">[see <linkhtml href="#Section_5.6">Warnings and Precautions (5.7)</linkhtml>] </content>or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[see <linkhtml href="#Section_5.2">Warnings and Precautions (5.2)</linkhtml>].</content>
<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Do not use tramadol hydrochloride extended-release tablets in patients taking MAOIs or within 14 days of stopping such treatment.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">phenelzine, tranylcypromine, linezolid<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">May reduce the analgesic effect of tramadol hydrochloride extended-release tablets and/or precipitate withdrawal symptoms.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Avoid concomitant use.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">butorphanol, nalbuphine, pentazocine, buprenorphine<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Muscle Relaxants</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Tramadol may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of tramadol hydrochloride extended-release tablets and/or the muscle relaxant as necessary.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Anticholinergic Drugs</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motility when tramadol hydrochloride extended-release tablets is used concomitantly with anticholinergic drugs.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Digoxin</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Follow patients for signs of digoxin toxicity and adjust the dosage of digoxin as needed.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Warfarin</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Post-marketing surveillance of tramadol has revealed rare reports of alteration of warfarin effect, including elevation of prothrombin times.<content stylecode="bold"></content>
<br/>
</td>
</tr>
<tr>
<td align="right" stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
<content stylecode="bold"></content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Monitor the prothrombin time of patients on warfarin for signs of an interaction and adjust the dosage of warfarin as needed.<content stylecode="bold"></content>
<br/>
</td>
</tr>
</tbody>
</table>